U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...

The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's ZENBEXUS™, the first CELMoD therapy, for treating adult patients with multiple myeloma who have had at least one prior therapy. This approval is based on Phase 3 trial results showing significant improvement in minimal residual disease-negative complete response.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.